
Slayback Pharma LLC has announced an agreement with The Everstone Group (“Everstone”) to invest up to US$50 million in Series B funding. The new capital will be used to expand and accelerate further Slayback’s already rich and differentiated pipeline of complex generic and specialty pharmaceutical products. In addition to the investment, Everstone Managing Directors Arjun…